Lucida Clinical Trials

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Obesity14 trials
• Type 2 diabetes6 trials
• High blood pressure3 trials
• Crohn's disease2 trials
• Osteoarthritis2 trials
• Diabetic neuropathy1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Ulcerative colitis1 trial

Phase

• Phase 210 trials
• Phase 39 trials

Status

• Recruiting9 trials
• Completed4 trials
• Active, not recruiting3 trials
• Not yet recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company18 trials
• Janssen Research & Development, LLC1 trial

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

• Recruiting

  A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

  NCT07641517· Phase 2· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  NCT07282600· Phase 3· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Jason Reich (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Paul Sepe (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Paul Sepe (principal investigator)

• Active, not recruiting

  A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

  NCT06948435· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

  NCT06952530· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

  NCT06948422· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

• Recruiting

  A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

  NCT05986292· Phase 2· Eli Lilly and Company· Source

  Contact: David Shih (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity7 recruiting
• Type 2 diabetes4 recruiting
• Crohn's disease2 recruiting
• Osteoarthritis2 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Eli Lilly and Company· Source

• Completed

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Eli Lilly and Company· Source